Filing Summary: Gl Partners Capital Management Ltd Just Disclosed New Sciclone Pharmaceuticals Inc Position

Filing Summary: Gl Partners Capital Management Ltd Just Disclosed New Sciclone Pharmaceuticals Inc Position

The New Gl Partners Capital Management Ltd Holding in Sciclone Pharmaceuticals Inc

Gl Partners Capital Management Ltd filed with the SEC SC 13D/A form for Sciclone Pharmaceuticals Inc. The form can be accessed here: 000114420416133591. As reported in Gl Partners Capital Management Ltd’s form, the filler as of late owns 9.3% or 4,750,116 shares of the Health Care–company.

Sciclone Pharmaceuticals Inc stake is a new one for the and it was filed because of activity on November 14, 2016. We feel this shows Gl Partners Capital Management Ltd’s positive view for the stock.

Sciclone Pharmaceuticals Inc Institutional Sentiment

Latest Security and Exchange filings show 128 investors own Sciclone Pharmaceuticals Inc. The institutional ownership in Q3 2015 is high, at 68.25% of the outstanding shares. This is decreased by 3075290 the total institutional shares. 34839438 were the shares owned by these institutional investors. In total 13 funds opened new Sciclone Pharmaceuticals Inc stakes, 49 increased stakes. There were 26 that closed positions and 52 reduced them.

Americafirst Capital Management Llc is an institutional investor bullish on Sciclone Pharmaceuticals Inc, owning 87524 shares as of Q3 2015 for less than 0.01% of its portfolio. Ranger Investment Management Lp owns 130840 shares or 0.05% of its portfolio. CT Nantahala Capital Management Llc have 0.16% of their stock portfolio for 170218 shares. Further, Matarin Capital Management Llc reported stake worth less than 0.01% of its US stock portfolio. The CA Sensato Investors Llc owns 1564682 shares. Sciclone Pharmaceuticals Inc is 2.03% of the manager’s US portfolio.

Business Profile

SciClone Pharmaceuticals, Inc. is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong. The Company’s lead product ZADAXIN (thymalfasin) is approved in approximately 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and certain cancers according to the local regulatory approvals, and for use as an immune system enhancer. In addition to ZADAXIN, the Company markets approximately seven partnered and in-licensed products in China. The Company’s development portfolio includes Angiomax, Neucardin, Loramyc, Cleviprex, RapidFilm, VIBATIV and SGX942. The Company sells ZADAXIN in various international markets through its subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL).

SEC Form 13D is filed within 10 days, by anyone who acquires beneficial ownership of 5%+ of any public firm. Activist investors and practices such as: company breakups, hostile takeovers, and change of control events, are permitted for this form filers. A filer must promptly update its 13D filing in case of acquisition or disposition of 1% or more of the securities that are the subject of the filing.

Insitutional Activity: The institutional sentiment increased to 1.18 in Q2 2016. Its up 0.06, from 1.12 in 2016Q1. The ratio improved, as 26 funds sold all SciClone Pharmaceuticals, Inc. shares owned while 41 reduced positions. 32 funds bought stakes while 47 increased positions. They now own 38.22 million shares or 3.91% more from 36.79 million shares in 2016Q1.

Bogle Investment Mgmt Limited Partnership De has 212,150 shares for 0.19% of their US portfolio. Gsa Prns Limited Liability Partnership holds 0.15% of its portfolio in SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) for 209,113 shares. Franklin holds 0.03% of its portfolio in SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) for 4.64M shares. Profund Limited Liability reported 10,830 shares or 0.01% of all its holdings. Invesco has 972,840 shares for 0% of their US portfolio. State Street Corporation last reported 1.25M shares in the company. Glenmede Tru Communications Na owns 305,073 shares or 0.02% of their US portfolio. Clarivest Asset Mgmt Ltd Liability Com accumulated 159,545 shares or 0.06% of the stock. State Of Tennessee Treasury Department holds 39,807 shares or 0% of its portfolio. The Texas-based Texas Permanent School Fund has invested 0.01% in SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN). Credit Suisse Ag holds 0% or 117,155 shares in its portfolio. Wells Fargo Co Mn accumulated 0% or 20,320 shares. National Bank Of America Corp De accumulated 8,448 shares or 0% of the stock. Renaissance Techs Lc, a New York-based fund reported 1.16 million shares. Moreover, New York State Teachers Retirement Sys has 0% invested in SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) for 41,221 shares.

Insider Transactions: Since August 12, 2016, the stock had 0 insider purchases, and 12 insider sales for $10.10 million net activity. Xie Lan also sold $340,221 worth of SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) on Friday, August 12. Cheung Wilson Wai-Shun had sold 1,475 shares worth $14,750. Shares for $5.02M were sold by Blobel Friedhelm on Wednesday, August 17. Shares for $1.24 million were sold by Hawkins Richard J. On Friday, August 12 King Robert sold $506,623 worth of the stock or 48,667 shares. CHANG NANCY T also sold $257,896 worth of SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) on Friday, August 26. 31,083 shares were sold by Meng Chuncai, worth $323,574 on Friday, August 12.

The stock increased 2.60% or $0.25 on November 11, hitting $9.85. SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) has declined 22.20% since April 12, 2016 and is downtrending. It has underperformed by 27.18% the S&P500.

SciClone Pharmaceuticals, Inc. is a pharmaceutical company. The company has a market cap of $504.71 million. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. It has a 13.16 P/E ratio. The Firm operates in two divisions: China and the Rest of the World, including its activities in the United States and Hong Kong.

More notable recent SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) news were published by: Marketwatch.com which released: “Virtual Stock Exchange” on October 28, 2009, also Prnewswire.com with their article: “SciClone Reports Third Quarter 2016 Financial Results” published on November 09, 2016, Prnewswire.com published: “SciClone Pharmaceuticals To Report Third Quarter 2016 Financial Results On …” on October 25, 2016. More interesting news about SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) were released by: Quotes.Wsj.com and their article: “DOW JONES, A NEWS CORP COMPANY” published on February 12, 2011 as well as Nasdaq.com‘s news article titled: “Sciclone Pharmaceuticals Inc (SCLN) President & CEO Friedhelm Blobel Sold $5 …” with publication date: August 19, 2016.

According to Zacks Investment Research, “Sciclone Pharmaceuticals, Inc. develops and commercializes novel medicines for treating a broad range of the world’s most serious diseases. They have focused their current product development and commercial activities on the following diseases: hepatitis C, hepatocellular carcinoma, malignant melanoma, hepatitis B, HIV, drug-resistant tuberculosis, cystic fibrosis and others.”

SCLN Company Profile

SciClone Pharmaceuticals, Inc. (SciClone), incorporated on June 26, 2003, is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company’s business is focused primarily in the People’s Republic of China. The Firm operates in two divisions: China and the Rest of the World, including its activities in the United States and Hong Kong. The Company’s lead product ZADAXIN (thymalfasin) is approved in over 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and certain cancers according to the local regulatory approvals, and for use as an immune system enhancer. In addition to ZADAXIN, SciClone markets approximately seven partnered and in-licensed products in China. The Firm sells ZADAXIN in various international markets through its subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment